While we aim to keep the information up to date and correct, there will inevitably be gaps or mistakes. Please help us to identify any issues by sending an email to contact@oncokb.org, or use the feedback button that appears next to alterations in cBioPortal.

Stay tuned for future data updates (improved annotations, new alterations), as well as new features. You can follow us on LinkedIn (OncoKB), or subscribe to our low-volume email list for updates.

When using OncoKB™, please cite: Suehnholz et al., Cancer Discovery 2023 and Chakravarty et al., JCO PO 2017.

June 26, 2025Data version: v4.30

Updated Therapeutic Implications

  • Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)
LevelGeneMutationCancer TypeLevel-Associated Drug(s) in OncoKB™Drug(s) Added to OncoKB™Evidence
1ROS1FusionsNon-Small Cell Lung CancerCrizotinib, Entrectinib, Repotrectinib (Level 1)Taletrectinib (Level 1)FDA approval of taletrectinib;

PMID: 40179330
1ERBB2Oncogenic MutationsNon-Small Cell Lung CancerTrastuzumab Deruxtecan (Level 1)Sevabertinib, Zongertinib (Level 3A)Abstract: Loong, HH. et al., ASCO 2025;

PMID: 40293180

    May 20, 2025Data version: v4.29

    • Updated Therapeutic Implications - Promotion of tumor type-specific level of evidence for an alteration
    GeneMutationCancer TypeLevel-associated Drug(s) in OncoKB™Previous LevelUpdated LevelEvidence
    KRASOncogenic MutationsLow-Grade Serous Ovarian CancerDrug(s) added to OncoKB™:
    Avutometinib + Defactinib (Level 1)

    Drug(s) remaining in OncoKB™:
    Binimetinib, Cobimetinib, Trametinib (Level 4)
    4 (KRAS G12A/D/R/S/V previously Level 3B)1FDA approval of avutometinib plus defactinib; Abstract: Grisham et al. Abstract #814605, 2025 SGO Annual Meeting on Women’s Cancer

      April 30, 2025Data version: v4.28

      March 28, 2025Data version: v4.27

      • Updated Therapeutic Implications - New alteration(s) with a tumor type-specific level of evidence
      LevelGeneMutationCancer TypeDrug(s) Added to OncoKB™Evidence
      4ERBB2Oncogenic MutationsBiliary Tract CancerNeratinib, Trastuzumab Deruxtecan, Pertuzumab + TrastuzumabPMID: 36746967, 38710187, 38748939

      • Updated Therapeutic Implications - Promotion of tumor type-specific level of evidence for an alteration
      GeneMutationCancer TypeLevel-associated Drug(s) in OncoKB™Previous LevelUpdated LevelEvidence
      ERBB2Oncogenic MutationsBreast CancerDrug(s) added to OncoKB™:
      Neratinib + Trastuzumab + Fulvestrant (Level 2)

      Drug(s) remaining in OncoKB™:
      Neratinib (Level 3A)
      3A2Inclusion in Breast Cancer NCCN Guidelines V3.2025; PMID: 37597578
      • Updated Therapeutic Implications - Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)
      LevelGeneMutationCancer TypeLevel-Associated Drug(s) in OncoKB™Drug(s) Added to OncoKB™Evidence
      1NF1Oncogenic MutationsNeurofibromaSelumentinib (Level 1)Mirdametinib (Level 1)FDA approval of mirdametinib; PMID: 39514826

        February 27, 2025Data version: v4.26

        GeneMutationCancer TypeLevel-associated Drug(s) in OncoKB™Previous LevelUpdated LevelEvidence
        FGFR1FusionsPancreatic CancerDrug(s) promoted in OncoKB™:
        Erdafitinib (Level 2, previously Level 4)

        Drug(s) remaining in OncoKB™:
        Fexagratinib (Level 4)
        42Inclusion in Pancreatic Cancer NCCN Guidelines V2.2025; PMID: 37541273
        FGFR2FusionsPancreatic CancerDrug(s) promoted in OncoKB™:
        Erdafitinib (Level 2, previously Level 4)

        Drug(s) remaining in OncoKB™:
        Fexagratinib (Level 4)
        42Inclusion in Pancreatic Cancer NCCN Guidelines V2.2025; PMID: 37541273
        FGFR2Oncogenic MutationsNon-Small Cell Lung CancerDrug(s) promoted in OncoKB™:
        Erdafitinib (Level 2, previously Level 4)

        Drug(s) remaining in OncoKB™:
        Fexagratinib, Lirafugratinib (Level 4)
        42Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V3.2025; PMID: 37541273
        FGFR3Oncogenic MutationsNon-Small Cell Lung CancerDrug(s) promoted in OncoKB™:
        Erdafitinib (Level 2, previously Level 4)

        Drug(s) remaining in OncoKB™:
        Fexagratinib (Level 4)
        42Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V3.2025; PMID: 37541273
        • Updated Therapeutic Implications - Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)
        LevelGeneMutationCancer TypeLevel-Associated Drug(s) in OncoKB™Drug(s) Added to OncoKB™Evidence
        1BRAFV600EColorectal CancerEncorafenib + Cetuximab (Level 1)Encorafenib + Cetuximab + FOLFOX Regimen (Level 1)FDA approval of encorafenib with cetuximab and mFOLFOX6; PMID: 39863775

          January 30, 2025Data version: v4.25

          • Happy New Year! As of January 30th, 2025, fifteen Level 1, twelve Level 2, eighteen Level 3 and eleven Level 4 treatments for unique biomarker-selected indications were added to OncoKB. A table summarizing these changes can be found here here. The “Precision Oncology: 2024 in Review” article can be found here.
          • Updated therapeutic implications - New alteration(s) with a tumor type-specific level of evidence
            LevelGeneMutationCancer TypeDrug(s)Evidence
            2ERBB2Oncogenic MutationsCervical CancerNeratinibInclusion in Cervical Cancer NCCN Guidelines V1.2025; PMID: 38211393
          • Updated therapeutic implications - Promotion of tumor type-specific level of evidence for an alteration(s)
            GeneMutationCancer TypeLevel-associated Drug(s) in OncoKB™Previous LevelUpdated LevelEvidence
            KRASG12CSmall Bowel Cancer
            Drug(s) promoted in OncoKB™:
            Adagrasib (Level 2, previously Level 3A)

            Drug(s) added to OncoKB™:
            Sotorasib (Level 2)
            3A2Inclusion in Small Bowel Adenocarcinoma NCCN Guidelines V1.2025; PMID: 32955176, 37099736, 36546659, 34919824
          • Updated therapeutic implications - Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)
            LevelGeneMutationCancer TypeLevel-associated Drug(s) in OncoKB™Drug(s) updated in OncoKB™Evidence
            1ALKFusionsNon-Small Cell Lung Cancer
            Alectinib, Brigatinib, Certinib, Crizotinib, Lorlatinib (Level 1)

            NVL-655 (Level 3A)
            Ensartinib (Level 1)FDA approval of ensartinib; PMID: 34473194
            1KRASG12CColorectal Cancer
            Sensitivity
            Adagrasib + Cetuximab (Level 1)

            Adagrasib + Panitumumab, Sotorasib + Cetuximab, Sotorasib + Panitumumab (Level 2)

            Binimetinib, Cobimetinib, Trametinib (Level 4)

            Resistance
            Cetuximab, Panitumumab, Tucatinib + Trastuzumab (Level R1)
            Sotorasib + Panitumumab (Level 1)FDA approval of sotorasib with panitumumab; PMID: 37870968
          • Addition of 2 new genes:

          December 19, 2024Data version: v4.24

          November 26, 2024Data version: v4.23

          • Updated therapeutic implications - New alteration(s) with a tumor type-specific level of evidence
            LevelGeneMutationCancer TypeDrug(s)Evidence
            1KMT2AFusionsMixed Phenotype Acute LeukemiaRevumenibFDA approval of revumenib; PMID: 39121437
          • Updated therapeutic implications - Addition of sensitivity-associated therapy(s) for an alteration(s) with a tumor type-specific resistance level of evidence
            GeneMutationCancer TypeDrug(s) remaining in OncoKB™Drug(s) added to OncoKB™Updated Sensitivity LevelUpdated Resistance LevelEvidence
            NTRK1G595RAll Solid TumorsLarotrectinib (Level R1), Entrectinib (Level R2)
            Selitrectinib (Level 3A)

            Zurletrectinib (Level 4)
            3AR1PMID: 32133433, 33004339, 28578312, 38902532, 34625502
            NTRK3G623RAll Solid TumorsLarotrectinib (Level R1)
            Selitrectinib (Level 3A)

            Zurletrectinib (Level 4)
            3AR1PMID: 28578312, 34030125, 37262390, 38902532, 34625502
          • Updated therapeutic implications - Promotion of tumor type-specific level of evidence for an alteration(s)
            GeneMutationCancer TypeLevel-associated Drug(s) in OncoKB™Previous LevelUpdated LevelEvidence
            KMT2AFusionsAcute Myeloid Leukemia, B-cell Lymphoblastic Leukemia/LymphomaRevumenib (Level 3A)3A1FDA approval of revumenib; PMID: 39121437
          • Updated therapeutic implications - Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)
            LevelGeneMutationCancer TypeLevel-associated Drug(s) in OncoKB™Drug(s) updated in OncoKB™Evidence
            1NTRK1/2/3FusionsAll Solid TumorsEntrectinib, Larotrectinib, Repotrectinib (Level 1)Zurletrectinib (Level 4)PMID: 38902532
          • Updated therapeutic implications - Removal of therapy(s) associated with a tumor type-specific leveled alteration(s) (without changing the alteration's highest level of evidence)
            GeneMutationCancer TypeCurrent Level of EvidenceDrug(s) removed from OncoKB™Drug(s) remaining in OncoKB™Evidence
            PIK3CAH1047RAll Solid Tumors4LOXO-783, LOXO-783 + Aromatase Inhibition Therapy + Abemaciclib, LOXO-783 + Fulvestrant, LOXO-783 + Fulvestrant + Abemaciclib, LOXO-783 + LY3484356, LOXO-783 + LY3484356 + Abemaciclib, LOXO-783 + Paclitaxel (Level 4)RLY-2608, RLY-2608 + Fulvestrant (Level 4)Discontinuation of LOXO-783 development
          • Addition of 6 new genes:

          October 24, 2024Data version: v4.22

          September 25, 2024Data version: v4.21

          • Updated therapeutic implications - New alteration(s) with a tumor type-specific level of evidence
            LevelGeneMutationCancer TypeDrug(s)Evidence
            3AALKF1174L/C, F1245Y/V, R1275Q/LNeuroblastomaLorlatinibPMID: 37012551, 26554404, 38032104, 27483357
            3AMETH1094Y, F1200INon-Small Cell Lung CancerElzovantinibPMID: 38564707
            4METN1100S, V1092I, H1106D, R1170Q, M1250TNon-Small Cell Lung CancerElzovantinib, Capmatinib, TepotinibPMID: 38564707
          • Updated therapeutic implications - Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)
            LevelGeneMutationCancer TypeLevel-associated Drug(s) in OncoKB™Drug(s) updated in OncoKB™Evidence
            1EGFRExon 19 in-frame deletions, L858RNon-Small Cell Lung CancerAfatinib, Dacomitinib, Erlotinib, Erlotinib + Ramucirumab, Gefitinib, Osimertinib, Osimertinib + Chemotherapy (Level 1); Amivantamab + Chemotherapy (Level 2); Amivantamab + Lazertinib, Patritumab Deruxtecan (Level 3A)Amivantamab + Lazertinib (Level 1; Promoted from Level 3A)FDA approval of Amivantamab + Lazertinib; PMID: 38924756
          • Addition of 8 new genes:

          August 15, 2024Data version: v4.20

          July 4, 2024Data version: v4.19

          • We updated the level 2 association for actionable POLE and POLD1 mutations in colorectal cancer and small bowel adenocarcinoma for immunotherapy to only include known oncogenic mutations in the exonuclease domain.

          July 2, 2024Data version: v4.18

          • Release of OncoKB™ SOP v4.1
          • Updated HUGO symbol for gene SLC9A3R1 to NHERF1
          • Updated therapeutic implications - Promotion of tumor type-specific level of evidence for an alteration(s)
            GeneMutationCancer TypeLevel-associated Drug(s) in OncoKB™Previous LevelUpdated LevelEvidence
            KRASG12CColorectal Cancer
            Drug(s) remaining in OncoKB™:
            Sensitivity
            Adagrasib + Cetuximab, Adagrasib + Panitumumab, Sotorasib + Cetuximab, Sotorasib + Panitumumab (Level 2)

            Resistance
            Tucatinib + Trastuzumab, Cetuximab, Panitumumab (Level R1)

            Drug(s) promoted in OncoKB™:
            Adagrasib + Cetuximab (Level 1)
            21FDA approval of Adagrasib + Cetuximab; PMID: 38587856
            KRASG12CBiliary Tract CancerAdagrasib3A2Inclusion in NCCN Biliary Tract Cancer Guidelines V2.2024; PMID: 37099736
          • Updated therapeutic implications - Addition of therapy(s) associated with a tumor type-specific leveled alteration(s) (without changing the alteration's highest level of evidence)
            GeneMutationCancer TypeCurrent Level of EvidenceDrug(s) remaining in OncoKB™Drug(s) added to OncoKB™Evidence
            EGFRExon 19 in-frame deletion, L858RNon-Small Cell Lung Cancer1Erlotinib, Afatinib, Gefitinib, Dacomitinib, Erlotinib + Ramucirumab, Osimertinib (Level 1); Patritumab Deruxtecan (Level 3A)Osimertinib + Chemotherapy (Level 1); Amivantamab + Chemotherapy (Level 2); Amivantamab + Lazertinib (Level 3A)FDA approval of Osimertinib with Chemotherapy; Inclusion of Amivantamab + Chemotherapy in NCCN Non-Small Cell Lung Cancer Guidelines V5.2024; PMID: 37937763, 37710001, 37879444, 38924756
            EGFRS768I, L861Q, G719XNon-Small Cell Lung Cancer1Afatinib (Level 1); Osimertinib (Level 2); Patritumab Deruxtecan (Level 3A)Erlotinib, Gefitinib, Dacomitinib, Amivantamab + Chemotherapy (Level 2); Amivantamab + Lazertinib (Level 3A)Inclusion of Erlotinib, Gefitinib, Dacomitinib and Amivantamab + Chemotherapy in NCCN Non-Small Cell Lung Cancer Guidelines V5.2024; PMID: 37879444, 25668120, 35770100; Abstract: Cho, B.C. et al., Abstract #8516, ASCO 2024
            ERBB2AmplificationBiliary Tract Cancer2Trastuzumab + PertuzumabTucatinib + Trastuzumab (Level 2)Inclusion in NCCN Biliary Tract Cancer Guidelines V2.2024; PMID: 37751561
          • Updated therapeutic implications - Changed drug specific tumor-type level of evidence for an alteration-tumor type-drug association currently in OncoKB (without changing the alteration's highest level of evidence)
            LevelGeneMutationCancer TypeDrug(s) remaining in OncoKB™Drug(s) changed in OncoKB™Evidence
            1NTRK1, NTRK2, NTRK3FusionsAll Solid TumorsLarotrectinib, Entrectinib (Level 1); Repotrectinib (Level 3A)Repotrectinib (Level 1)FDA approval of Repotrectinib; ; Abstract: Solomon, B.J., et al., Abstract #1372P, Ann Oncol Vol 34, Suppl 2, 2023
          • Addition of 5 new genes:

          June 4, 2024Data version: v4.17

          May 1, 2024Data version: v4.16

          March 21, 2024Data version: v4.15

          • Updated therapeutic implications - New alteration(s) with a tumor type-specific level of evidence
            Level(s)GeneMutationCancer TypeDrug(s)Evidence
            3AEGFRL718QNon-Small Cell Lung CancerAfatinibPMID: 32146032, 32193290, 31315676
            R2OsimertinibPMID: 27257132, 29506987, 33937055, 31205925, 34926262, 31315676, 32146032
            R2EGFRL792FNon-Small Cell Lung CancerOsimertinibPMID: 35932642, 28093244, 29506987, 35422503
          • Updated therapeutic implications - Addition of sensitivity-associated therapy(s) for an alteration(s) with a tumor type-specific resistance level of evidence
            GeneMutationCancer TypeDrug(s) remaining in OncoKB™Drug(s) added to OncoKB™Updated Sensitivity LevelUpdated Resistance LevelEvidence
            EGFRG724SNon-Small Cell Lung CancerOsimertinib (Level R2)Afatinib (Level 3A)3AR2PMID: 32093857, 35979997, 33209641, 34590038, 30405134
          • Updated therapeutic implications - Demotion of tumor type-specific level of evidence for an alteration
            GeneMutationCancer TypeLevel-associated Drug(s) in OncoKB™Previous LevelUpdated LevelEvidence
            AKT1Oncogenic Mutations (excluding E17K, which remains Level 1)Breast CancerCapivasertib + Fulvestrant12To adhere to the FDA-drug label and CDx for Capivasertib, Level 1 assignment will be only for AKT1 E17K detected by the FoundationOne CDx test. All other AKT1 oncogenic mutations are Level 2 per their inclusion in the NCCN Breast Cancer Guidelines V2.2024
            PIK3CAOncogenic Mutations (excluding R88Q, N345K, C420R, E542K, E545A, E545D, E545Q, E545K, E545G, Q546E, Q546K, Q546R, Q546P, M1043V, M1043I, H1047Y, H1047R, H1047L and G1049R, which remain Level 1)Breast Cancer
            Drug(s) remaining in OncoKB™:
            Capivasertib + Fulvestrant (Level 1), Alpelisib + Fulvestrant (Level 2)

            Drug(s) demoted in OncoKB™:
            Capivasertib + Fulvestrant (Level 2)
            12To adhere to the FDA-drug label and CDx for Capivasertib, Level 1 assignment will be only for the PIK3CA alterations detected by the FoundationOne CDx test. All other PIK3CA oncogenic mutations are Level 2 per their inclusion in the NCCN Breast Cancer Guidelines V2.2024
            FGFR1AmplificationLung Squamous Cell CarcinomaErdafitinib3ANo LevelLimited response rate to EGFR inhibitors for FGFR1-amplified lung squamous cell carcinoma; Discontinuation of infigratinib; PMID: 37909331, 37606995
          • Updated therapeutic implications - Promotion of tumor type-specific level of evidence for an alteration
            GeneMutationCancer TypeLevel-associated Drug(s) in OncoKB™Previous LevelUpdated LevelEvidence
            KRASG12CAmpullary CancerSotorasib, Adagrasib3B2Inclusion in NCCN Ampullary Adenocarcinoma Guidelines V1.2024; PMID: 32955176
            EGFRL718VNon-Small Cell Lung Cancer
            Drug(s) remaining in OncoKB™:
            Osimertinib (Level R2), Afatinib (Level 4)

            Drug(s) promoted in OncoKB™:
            Afatinib (Level 3A)
            43AIto, T., et al., Current Prob. in cancer, 2023; PMID: 35365043, 31757379, 29571986
          • Updated therapeutic implications - Addition of therapy(s) associated with a tumor type-specific leveled alteration(s) (without changing the alteration's highest level of evidence)
            GeneMutationCancer TypeCurrent Level of EvidenceDrug(s) remaining in OncoKB™Drug(s) added to OncoKB™Evidence
            EGFRExon 20 in-frame insertionsNon-Small Cell Lung Cancer1Amivantamab, Mobocertinib (Level 1); Erlotinib, Afatinib, Gefitinib (Level R1)Amivantamab + Chemotherapy (Level 1)FDA approval of Amivantamab + Carboplatin + Pemetrexed; PMID: 37870976
          • Addition of 4 new genes:

          February 8, 2024Data version: v4.14

          • Updated therapeutic implications - New alteration(s) with a tumor type-specific level of evidence
            LevelGeneMutationCancer TypeDrug(s)Evidence
            3AMDM2AmplificationIntimal SarcomaMilademetanPMID: 37369013
          • Updated therapeutic implications - Removal of therapy(s) and changed tumor type-specific level of evidence for an alteration(s)
            GeneMutationCancer TypePrevious LevelCurrent Level of EvidenceDrug(s) remaining in OncoKB™Drug(s) removed from OncoKB™Evidence
            FGFR2FusionsBladder CancerLevel 1No Level
            Erdafitinib (Level 1)
            AZD4547 (Level 4)
            Erdafitinib, AZD4547Amendment to the FDA-drug label for Erdafitinib; 4/25 (16%) response rate for FGFR2/3 fusion+ bladder cancer, 0/6 (0%) response for FGFR2 fusion+ bladder cancer; PMID: 31340094
          • Updated therapeutic implications - Demotion of tumor type-specific level of evidence for an alteration(s)
            GeneMutationCancer TypeDrug(s)Previous LevelCurrent LevelReason
            FGFR3Fusions (excluding FGFR3-TACC3 Fusion and FGFR3-BAIAP2L1 Fusion which remain Level 1)Bladder CancerErdafitinib12Adherence to FDA-drug label and CDx for Erdafitinib; Inclusion in NCCN Bladder Cancer Guidelines V3.2023; PMID: 37870920
          • Updated therapeutic implications - Promotion of tumor type-specific level of evidence for an alteration(s)
            GeneMutationCancer TypeDrug(s)Previous LevelCurrent LevelReason
            FGFR3S371C, G380R, K650Bladder CancerErdafitinib3A2 Adherence to FDA-drug label and CDx for Erdafitinib; Inclusion in NCCN Bladder Cancer Guidelines V3.2023; PMID: 37870920
            FGFR3Oncogenic Mutations (excluding G370C, R248C, S249C, Y373C which remain Level 1)42
            MDM2AmplificationDedifferentiated Liposarcoma, Well-Differentiated Liposarcoma
            Drug(s) remaining in OncoKB™:
            Milademetan (Level 4)

            Drug(s) added to OncoKB™:
            Brigimadlin (Level 3A)
            43APMID: 37269344
          • Addition of 14 new genes:

          January 17, 2024

          • Happy New Year! As of December 31, 2023, 11 level 1, 7 level 2, 4 level 3 and 3 level 4 treatments for unique biomarker-selected indications were added to OncoKB. A table summarizing these changes can be found here. The Precision Oncology: 2023 in review article can be found here.

          December 21, 2023Data version: v4.13

          December 6, 2023Data version: v4.12

          November 13, 2023Data version: v4.11

          October 24, 2023Data version: v4.10

          • Updated therapeutic implications - Changed level of evidence
            GeneMutationCancer TypeDrug(s)Previous LevelCurrent LevelReason
            KRASG12CColorectal Cancer
            Drug(s) remaining in OncoKB™:
            Adagrasib + Cetuximab (Level 3A)

            Drug(s) added to OncoKB™:
            Adagrasib + Panitumumab; Sotorasib + Cetuximab; Sotorasib + Panitumumab
            3A2Inclusion in Colon Cancer NCCN guidelines v3.2023 and in Rectal Cancer NCCN guidelines v5.2023; PMID: 36546659; Abstract: Kuboki et al. Abstract# 45MO, ESMO 2022.
          • Updated therapeutic implications - Addition of therapies for variants with a level of evidence
            GeneMutationCancer TypeCurrent Level of EvidenceDrug(s) remaining in OncoKB™Drug(s) added to OncoKB™Evidence
            BRAFV600ENon-Small Cell Lung Cancer1Dabrafenib + Trametinib (Level 1)Encorafenib + Binimetinib (Level 1)FDA approval of Encorafenib + Binimetinib for BRAF V600E NSCLC; PMID: 37270692
          • Addition of 6 new genes:

          October 2, 2023Data version: v4.9

          September 1, 2023Data version: v4.8

          July 28, 2023Data version: v4.7

          July 12, 2023Data version: v4.6

          May 19, 2023Data version: v4.5

          April 12, 2023Data version: v4.4

          • Release of NEW cancer-type pages, allowing easier visualization of variant and cancer type-specific clinical implications. As an example, see tables for treatment, diagnostic and prognostic implications on the BCR-ABL1, B-lymphoblastic leukemia/lymphoma cancer-type page.
          • Release of therapeutic descriptions for all alteration- and tumor type-specific leveled associations. These are located on the variant- and cancer-type pages. See BRAF V600E as an example.
          • Addition of 1 new gene:

          March 22, 2023Data version: v4.3

          February 10, 2023Data version: v4.2

          • Changed annotation and addition of therapies for variants with a level of evidence
            GeneMutationCancer TypePrevious Level of EvidenceCurrent Level of EvidenceDrug(s) remaining in OncoKB™Drug(s) added to OncoKB™Evidence
            ESR1Oncogenic Ligand-Binding Domain Missense Mutations (310_547)Breast Cancer3A1Fulvestrant
            (Level 3A)
            Elacestrant
            (Level 1)
            FDA approval of elacestrant in breast cancer
            ESR1Oncogenic Ligand-Binding Domain In-Frame Insertions or Deletions (310_547)Breast Cancer3A3AFulvestrant
            (Level 3A)
            Elacestrant
            (Level 3A)
            FDA approval of elacestrant in breast cancer (Level 1 ESR1 mutations limited to those specified in corresponding FDA-approved CDx)

          February 1, 2023Data version: v4.1

          • Addition of 5 new genes:
          • To better align with the FDA drug label, all KIT oncogenic mutations in GIST are now level 1 in association with Imatinib, Sunitinib, Ripretinib, and Regorafenib. Previously, only known sensitizing KIT exon 9, 11, 13, 14, 17 and 18 alterations were considered level 1 in this indication.
          • With the recent FDA approval of Tucatinib + Trastuzumab for patients with RAS wildtype, HER2-positive colorectal cancer the following OncoKB changes have been made:

          January 5, 2023

          • Happy New Year! 2022 brought many changes to the landscape of precision oncology. The OncoKB 2022 year in review can be found HERE.

          December 22, 2022Data version: v4.0

          • Happy Holidays! OncoKB mutation effect descriptions are now available to all users on our website, in cBioPortal and through our API. These descriptions summarize the data supporting the biological and oncogenic effect designation for each alteration, and represent seven years of effort from the OncoKB scientific team.
          • Updated therapeutic implications - Addition of therapies for variants with a level of evidence
            GeneMutationCancer TypeCurrent Level of EvidenceDrug(s) remaining in OncoKB™Drug(s) added to OncoKB™Evidence
            KRASG12CNon-Small Cell Lung Cancer1SotorasibAdagrasib
            (Level 1)
            FDA approval of adagrasib in NSCLC; Abstract: Spira et al. Abstract# 9002, ASCO 2022

          December 13, 2022Data version: v3.19

          November 30, 2022Data version: v3.18

          October 28, 2022Data version: v3.17

          September 6, 2022Data version: v3.16

          July 25, 2022Data version: v3.15

          June 6, 2022Data version: v3.14

          May 5, 2022Data version: v3.13

          • We loved connecting with so many of you at the 2022 AACR annual meeting. If you missed our poster, you can download a copy here
          • Updated therapeutic implications - Addition of therapies for variants with a level of evidence
            GeneMutationCancer TypeCurrent Level of EvidenceDrug(s) remaining in OncoKB™Drug(s) added to OncoKB™Evidence
            EGFRS768I, L861Q, G719Non-Small Cell Lung Cancer1AfatinibOsimertinib
            (Level 2)
            Listing in NSCLC NCCN v1.2022; PMID: 31825714
            ROS1FusionsNon-Small Cell Lung Cancer1Crizotinib, EntrectinibCeritinib
            (Level 2)
            Listing in NSCLC NCCN v1.2022; PMID: 28520527
            ROS1FusionsNon-Small Cell Lung Cancer1Crizotinib, EntrectinibLorlatinib
            (Level 2)
            Listing in NSCLC NCCN v1.2022; PMID: 31669155
            METAmplificationsNon-Small Cell Lung Cancer2CrizotinibCapmatinib
            (Level 2)
            Listing in NSCLC NCCN v1.2022; PMID: 32877583
            METAmplificationsNon-Small Cell Lung Cancer2CrizotinibTepotinib
            (Level 2)
            Listing in NSCLC NCCN v1.2022; Abstract: Le et al. Abstract# 9021, ASCO 2021
            KRASG12CPancreatic Cancer3AAdagrasibSotorasib
            (Level 3A)
            Abstract: Strickler et al. Abstract# 360490, ASCO GI 2022
            FGFR2FusionsCholangiocarcinoma1Infigratinib, PemigatinibFutibatinib
            (Level 3A)
            Abstract: Goyal et al. Abstract# CT010, AACR 2021
          • Addition of 1 new gene:

          March 29, 2022Data version: v3.12

          • Updated therapeutic implications - 2 new associations
            LevelGeneMutationCancer TypeDrug(s)Evidence
            2BRCA2Oncogenic MutationsUterine SarcomaOlaparib, Rucaparib, NiraparibListing in Uterine cancer NCCN v1.2022; PMID: 33970096
            2PALB2Oncogenic MutationsPancreatic CancerRucaparibListing in Pancreatic cancer NCCN v1.2022; PMID: 33970687, 34351646, 30051098
          • Changed Annotation
            GeneMutationCancer TypeDrug(s)Previous LevelCurrent LevelReason
            BRCA1, BRCA2Oncogenic MutationsPancreatic CancerPARPi3A2Listing of Rucaparib in Pancreatic cancer NCCN v1.2022; PMID: 33970687, 34351646, 30051098
          • Statistically recurrent hotspots per cancerhotspots.org that have not been curated by OncoKB™ are now considered "Likely Oncogenic" (the concept “Predicted Oncogenic” has been removed).
          • API information (https://www.oncokb.org/api/v1/info) now includes the software version which, together with the data version, can be used to update instances of local annotation.

          February 28, 2022Data version: v3.11

          January 7, 2022Data version: v3.10

          • In addition to the previously provided reference genome, gene pages will now include gene chromosomal locations. See BRAF as an example.
          • Updated therapeutic implications - 1 new association
            LevelGeneMutationCancer TypeDrug(s)Evidence
            4STK11Oncogenic MutationsNon-Small Cell Lung CancerBemcentinib + PembrolizumabAbstract: Li et al. Abstract # 602, JITC 2021

          November 29, 2021Data version: v3.9

          • Release of OncoKB™ SOP v2.2
          • New Genes Added:
          • Updated therapeutic implications: New variants with a level of evidence
            LevelGeneMutationCancer TypeDrug(s)Evidence
            1ABL1T315IChronic Myelogenous LeukemiaAsciminibFDA approval of Asciminib; Abstract: Hochhaus et al. Abstract #LBA-4, ASH 2020
            3AIDH1R132GliomaIvosidenibPMID: 29670690, 32530764
            3AKRASG12CColorectal CancerAdagrasib, Adagrasib + CetuximabAbstract: Weiss et al. Abstract# LBA6, ESMO 2021
            4MDM2AmplificationDedifferentiated Liposarcoma, Well-Differentiated LiposarcomaMilademetanPMID: 23400593
          • Updated therapeutic implications: Changed annotations
            GeneMutationCancer TypeDrug(s)Previous LevelCurrent LevelReason
            ABL1BCR-ABL1 FusionChronic Myelogenous LeukemiaAsciminib3A1FDA approval of Asciminib; PMID: 34407542
            BRCA1, BRCA2Oncogenic MutationsBreast CancerOlaparib, Talazoparib23AStrict adherence to FDA drug labels for olaparib and talazoparib
            MET Y1003mut Non-Small Cell Lung CancerTepotinib, Capmatinib13AStrict adherence to FDA drug labels for tepotinib and capmatinib
            MET Y1003mut Non-Small Cell Lung CancerCrizotinib23AStrict adherence to listing in NCCN Non-Small Cell Lung Cancer v7.2021
          • Updated therapeutic implications: Updated variant annotations to more accurately reflect the evidence
            LevelGenePrevious Variant AnnotationCurrent Variant AnnotationCancer TypeDrugEvidence
            1ALKOncogenic MutationsFusionsNon-Small Cell Lung CancerBrigatinibFDA drug label for brigatinib and adherence to OncoKB™ SOP v2.2
            2BRAFV600V600 (Excluding V600E, V600K)MelanomaBinimetinib + Encorafenib, Dabrafenib + Trametinib, Cobimetinib + VemurafenibThe NCCN Melanoma: Cutaneous v2.2021 lists “BRAF V600” and is not limited to V600E/K. Therefore, according to the OncoKB™ SOP v2.2 BRAF V600 is considered Level 2, while V600E/K are Level 1.
            2EZH2Oncogenic MutationsOncogenic Mutations (Excluding Y646F, A692V, Y646C, Y646S, Y646N, Y646H, A682G)Follicular LymphomaTazemetostatThe NCCN B-cell lymphoma v5.2021 lists “EZH2 mutation” and is not limited to the mutations listed in the FDA-approved CDx. Therefore, according to the OncoKB™ SOP v2.2 EZH2 Oncogenic Mutations are considered Level 2, with the exception of those mutations listed in the CDx, which are Level 1.
            2PIK3CAOncogenic MutationsOncogenic Mutations (Excluding E545G, Q546E, E545A, H1047R, C420R, H1047Y, Q546R, H1047L, E542K, E545D, E545K)Breast CancerAlpelisib+FulvestrantThe NCCN Breast Cancer V8.2021 lists “PIK3CA activating mutation” and is not limited to the mutations listed in the FDA-approved CDx. Therefore, PIK3CA Oncogenic Mutations by OncoKB™ SOP v2.2 are considered Level 2, with the exception of those mutations listed in the CDx, which are Level 1.
          • Updated therapeutic implications: Updated tumor type
            LevelGeneMutationPrevious Cancer TypeCurrent Cancer TypeDrugEvidence
            3APTCH1Truncating MutationsEmbryonal TumorMedulloblastomaSonidegib, VismodegibPMID: 24523439, 32923880, 26169613, 31362788, 29515801

          October 26, 2021Data version: v3.8

          October 7, 2021

          • OncoKB™ is the first somatic human genetic variant database to achieve FDA partial recognition! Read more about the scope of the recognition, the recognition process, and what it means for the knowledge base and our users on our About Page.

          September 29, 2021Data version: v3.7

          August 31, 2021Data version: v3.6

          • Updated therapeutic implications - 1 new association
            LevelGeneMutationCancer TypeDrug(s)Evidence
            2BRAFFusionsPilocytic AstrocytomaSelumetinibListing in CNS Cancer NCCN v1.2021; PMID: 31151904
          • Changed Annotation
            GeneMutationCancer TypeDrug(s)Previous LevelCurrent LevelReason
            IDH1R132CholangiocarcinomaIvosidenib3A1FDA approval of Ivosidenib; PMID: 32416072

          July 16, 2021Data version: v3.5

          June 17, 2021Data version: v3.4

          April 14, 2021Data version: v3.3

          March 12, 2021Data version: v3.2

          February 10, 2021Data version: v3.1

          January 14, 2021Data version: v3.0

          December 17, 2020Data version: v2.10

          November 13, 2020Data version: v2.9

          September 17, 2020Data version: v2.8

          August 28, 2020Data version: v2.7

          July 23, 2020Data version: v2.6

          July 9, 2020Data version: v2.5

          June 9, 2020Data version: v2.4

          May 11, 2020Data version: v2.3

          April 24, 2020

          • We have introduced an FAQ page where you can find answers to several frequently asked questions.

          April 23, 2020Data version: v2.2

          April 16, 2020

          • An updated version of the OncoKB™ Curation Standard Operating Procedure, v1.1, has been released. See the OncoKB™ About page or https://sop.oncokb.org.
          • We now show a comparison between the OncoKB™ and AMP/ASCO/CAP Levels of Evidence on the Levels of Evidence page.

          February 12, 2020Data version: v2.1

          December 20, 2019Data version: v2.0

          Introducing Simplified OncoKB™ Levels of Evidence:
          • New Level 2, defined as "Standard care biomarker recommended by the NCCN or other expert panels predictive of response to an FDA-approved drug in this indication" (formerly Level 2A).
          • Unified Level 3B, defined as "Standard care or investigational biomarker predictive of response to an FDA-approved or investigational drug in another indication" (combination of previous Levels 2B and 3B).
          We have implemented these changes for 2 reasons:
          1. To be consistent with the Joint Consensus Recommendation by AMP, ASCO and CAP and the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
          2. To reflect the clinical data that demonstrates patients with investigational predictive biomarkers for a specific tumor type based on compelling clinical evidence (currently Level 3A) are more likely to experience clinical benefit compared to patients with predictive biomarkers that are considered standard care in a different cancer type (previously Level 2B, now combined into Level 3B).

          December 12, 2019Data version: v1.24

          December 9, 2019

          We now require user logins for access to downloadable data files and API. OncoKB™ will continue to be accessible for no fee for research use in an academic setting, but a license will be required to use OncoKB™ for commercial and/or clinical purposes. Fees will be used to support future development and maintenance of OncoKB™. Please visit the registration page.

          August 28, 2019Data version: v1.23

          August 4, 2019Data version: v1.22

          • Updated therapeutic implications - 2 new associations
            LevelGeneMutationCancer TypeDrug(s)Evidence
            2ABRAFV600EHairy Cell LeukemiaVemurafenibListing in 3.2019 Hairy Cell Leukemia NCCN (PMID: 26352686)
            3AARAF, BRAF, RAF1, NRAS, KRAS, MAP2K2Oncogenic MutationsHistiocytic and Dendritic Cell NeoplasmsCobimetinibPMID: 30867592
          • Changed Annotation
            GeneMutationCancer TypeDrug(s)Previous LevelCurrent LevelReason
            BRAFD287H, D594, F595L, G466, G596, N581, S467L, V459LAll Solid TumorsPLX83944No level
            Re-review of PMID
            PMID: 28783719

            BRAF class III mutants are not necessarily sensitive to dimer disrupter RAF inhibitor PLX8394
          • Addition of 4 new genes:

          June 21, 2019Data version: v1.21

          • Improved Actionable Genes page
          • Updated the Cancer Genes list which now consists of 1039 genes (no longer referring to the Cancer Gene Census Tier 2 genes)
          • Updated therapeutic implications
            LevelUpdate
            1
            2A
            • BRAF - V600E - Colorectal Cancer - Encorafenib + Binimetinib + Cetuximab (previously level 3A)
            • ERBB2 - Amplification - Uterine Serous Carcinoma - Trastuzumab + Carboplatin-Paclitaxel (previously level 2B)

          May 9, 2019Data version: v1.20

          • Addition of Actionable Genes for Hematologic Malignancies
            LevelGeneMutationCancer TypeDrug
            1ABL1BCR-ABL1 fusionB-Lymphoblastic Leukemia/Lymphoma (BLL)Ponatinib
            Chronic Myelogenous Leukemia (CML)Bosutinib
            T315IBLL, CMLPonatinib
            FLT3Internal tandem duplications (ITD)Acute Myeloid Leukemia (AML)Gilteritinib
            Oncogenic MutationsMidostaurin + High Dose Chemotherapy
            R1ABL1T315IBLL, CMLImatinib, Dasatinib, Nilotinib, Bosutinib
            2AABL1BCR-ABL1 fusionBLLBosutinib, Nilotinib
            E255K, E255V, F317C, F317I, F317L, F317V, F359C, F359I, F359V, T315A, Y253HBLL, CMLBosutinib
            E255K, E255V, F359C, F359I, F359V, Y253HDasatinib
            F317C, F317I, F317L, F317V, T315A, V299LNilotinib
            3AABL1BCR-ABL1 fusionCMLAsciminib
            E255K, E255V, F359C, F359I, F359V, Y253HBLL, CMLDasatinib
            F317C, F317I, F317L, F317V, T315A, V299LNilotinib
            FLT3ITDAMLCrenolanib, Quizartinib
            4SF3B1Oncogenic MutationsAML, Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS)H3B-8800
            SRSF2
            U2AF1
            ZRSR2
          • Updated therapeutic implications
            LevelUpdate
            1
            • April 12, 2019: the FDA approved erdafitinib for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations (FGFR2 Fusions, FGFR3 Fusions or FGFR3 R248C, S249C, G370C, Y373C mutations), that has progressed during or following platinum-containing chemotherapy.
            4
            • MET - Fusions - All Tumors - Crizotinib (new association)
            • CDK12 - Truncating Mutations - All Tumors - Pembrolizumab, Nivolumab, Cemiplimab (new association)
          • Standardization of therapeutic names with NCI thesaurus
          • Addition of 37 new heme-, fusion-associated genes:

          January 24, 2019Data version: v1.19

          • Updated therapeutic implication
            LevelUpdate
            1
            • November 2, 2018: the FDA approved lorlatinib for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor or whose disease has progressed on alectinib or ceritinib for metastatic disease.
          • Addition of 16 new heme-associated genes:

          December 14, 2018Data version: v1.18

          • Inclusion of NTRK1 and NTRK3 Level R2 alterations to the Actionable Genes page
          • Updated therapeutic implications
            LevelUpdate
            1
            • November 26, 2018: the FDA approved larotrectinib for adult and pediatric patients with solid tumors that have an NTRK1, -2, or -3 gene fusion without a known acquired resistance mutation.
            2A
            • BRCA1/2 - Oncogenic Mutations - Breast Cancer - Talazoparib (new association)
            • RET - Fusions - Non-Small Cell Lung Cancer - BLU-667 (new association)
            3A
            • BRAF - V600E - Colorectal Cancer - Encorafenib + Binimetinib + Cetuximab (new association)
            • ERBB2 - Oncogenic Mutations - Non-Small Cell Lung Cancer - Ado-trastuzumab Emtansine (new association)
            • RET - Oncogenic Mutations - Medullary Thyroid Cancer - BLU-667 (new association)
            4
            • KDM6A - Oncogenic Mutations - Bladder Cancer - EZH2 inhibitors (new association)
          • Addition of 25 new heme-associated genes:

          November 2, 2018Data version: v1.17_patch_1

          • Updated therapeutic implication
            LevelUpdate
            2A
            • RET - Fusions - Non-Small Cell Lung Cancer - LOXO-292 (added as new association)

          October 26, 2018Data version: v1.17

          October 1, 2018Data version: v1.16

          August 20, 2018Data version: v1.15

          July 12, 2018Data version: v1.14

          • Updated therapeutic implications
            LevelUpdate
            1
            3A
            • EGFR - Exon 20 insertions - Non-small cell lung cancer - Poziotinib (added as new association)
            • ALK - G1202R - Non-small cell lung cancer - Lorlatinib (added as new association)
            • KIT - D816 mutations - Mastocytosis - Avapritinib (added as new association)
            • MTOR - E2014K, E2419K - Bladder cancer - Everolimus (updated association)
            • MTOR - L1460P, L2209V, L2427Q - Renal cell carcinoma - Temsirolimus (updated association)
            • MTOR - Q2223K - Renal cell carcinoma - Everolimus (updated association)
          • New Level 4 associations have been added:
            GeneMutationCancer TypeDrug
            ATMOncogenic MutationsProstate CancerOlaparib
            BRAFD287H, D594A, D594G, D594H, D594N, F595L, G464E, G464V, G466A, G466E, G466V, G469A, G469E, G469R, G469V, G596D, G596R, K601N, K601T, L597Q, L597V, N581I, N581S, S467L, V459LAll TumorsPLX8394
            CDKN2AOncogenic MutationsAll TumorsAbemaciclib, Palbociclib, Ribociclib
            EGFRA289V, R108K, T263PGliomaLapatinib
            EGFRAmplificationGliomaLapatinib
            EWSR1EWSR1-FLI1 FusionEwing SarcomaTK216
            FGFR1Oncogenic MutationsAll TumorsAZD4547, BGJ398, Debio1347, Erdafitinib
            FGFR2Oncogenic MutationsAll TumorsAZD4547, BGJ398, Debio1347, Erdafitinib
            KRASOncogenic MutationsAll TumorsKO-947, LY3214996, Ravoxertinib, Ulixertinib
            MTOROncogenic MutationsAll TumorsEverolimus, Temsirolimus
            NF1Oncogenic MutationsAll TumorsCobimetinib, Trametinib
            PTENOncogenic MutationsAll TumorsAZD8186, GSK2636771
            SMARCB1Oncogenic MutationsAll TumorsTazemetostat
          • Inclusion of Level R1 actionable alterations in Actionable Genes

          February 2, 2018Data version: v1.13

          • Updated therapeutic implications
            LevelUpdate
            1
            • November 6, 2017: the FDA approved vemurafenib for treatment of patients with Erdheim-Chester disease (histiocytosis) who harbor BRAF V600 mutations.
            3A
            • HRAS - Oncogenic Mutations - Head and Neck Squamous Cell Carcinoma - Tipifarnib (moved from 4 to 3A only for HNSCC)
          • Addition of a new gene: KLF5 (Zhang et al., Cancer Discovery, 2017).
          • Addition of new alterations and updates to existing alterations.

          October 26, 2017Data version: v1.12_patch_1

          August 17, 2017

          The following FDA-approvals have been incorporated into the Actionable Genes table:

          August 2, 2017

          • Introduced a curated list of cancer genes.
          • Addition of gene-alterations pages with alteration level annotation. e.g. BRAF V600E.
          • Improved search box that queries genes and alterations.

          May 15, 2017Data version: v1.10_patch_1

          • Brigatinib FDA-approval in ALK-positive NSCLC added as a new Level 1 association.
          • Amplification events for most Oncogenes and Deletions or Truncating mutations for most Tumor Suppressor have been annotated/updated.
          • Inclusion of literature from AACR 2017.
          • Addition of new alterations and updates to existing alteration annotations.

          April 5, 2017Data version: v1.9

          • Curation of 58 additional genes.
          • Gene alias information added to gene page and search box.
          • API updates.
          • Updated therapeutic implications
            LevelUpdate
            1
            • BRCA1/2 - Oncogenic Mutations - Ovarian Cancer - Niraparib FDA approval added
            • BRCA1/2 - Oncogenic Mutations - Ovarian Cancer - Rucaparib (new publication added)
            • Updated alterations for KIT - Gastrointestinal Stromal Tumor - Imatinib, Sunitinib, Regorafenib
            2A
            • Updated alterations for KIT - Gastrointestinal Stromal Tumor - Nilotinib, Dasatinib, Sorafenib
            • Updated alterations for KIT - Thymic cancer - Sunitinib, Sorafenib
            3A
            • BRAF V600 - Colorectal Cancer - Encorafenib + Binimetinib + Cetuximab (new association)
            • FGFR1 - Amplification - Lung Squamous Cell Carcinoma - AZD4547, Debio1347 (new abstract added)
            • FGFR2 - Fusions - Cholangiocarcinoma - BGJ398, Debio1347 (new abstract added)
            • Updated alterations for FGFR3 - Bladder cancer - JNJ-42756493, Debio1347
            • PIK3CA - Oncogenic Mutations - Breast cancer - Updated treatments and evidence
            4
            • BRAF V600 - Colorectal Cancer - Radiation + Trametinib + Fluorouracil (new association)
            • Updated alterations for FGFR3 - Breast cancer - Debio1347
            • KRAS - Wildtype - Updated treatments and evidence
            • KRAS - Oncogenic Mutations - Updated treatments and evidence
            • PIK3CA - Oncogenic Mutations - Breast cancer - Updated treatments and evidence
            • PTEN - Oncogenic Mutations - Breast cancer - Updated treatments and evidence

          March 7, 2017Data version: v1.8

          • Expanded selection of genes with Oncogene or Tumor Suppressor annotation.
          • Level 4 actionable genes are now accessible from the home page.
          • Updated therapeutic implications
            LevelUpdate
            1
            • Updated alterations for EGFR - Non-Small Cell Lung Cancer - EGFR TKIs
            • Updated alterations for KIT - Gastrointestinal Stromal Tumor - Imatinib, Sunitinib, Regorafenib
            2A
            • CDK4 - Amplification - Well-Differentiated Liposarcoma/Dedifferentiated Liposarcoma - Palbociclib, Abemaciclib (disease changed from Soft Tissue Sarcoma and Abemaciclib added)
            • TSC1 - Renal Cell Carcinoma - Everolimus (new association)
            3A
            • ESR1 - Oncogenic Mutations - AZD9496, Fulvestrant (new association)
            • FGFR1 - Amplification - Breast Cancer - Dovitinib (removed)
            • FGFR1 - Amplification - Lung Squamous Cell Carcinoma - Debio1347 (new association)
            • FGFR2 - Amplification - Breast Cancer - Dovitinib (removed)
            • FGFR2/3 - Fusions - Various cancer types - Debio1347 (new association)
            • FGFR3 - Hotspots - Bladder Cancer - Debio1347, JNJ-42756493 (new association)
            • KRAS - Oncogenic Mutations - Colorectal Cancer - Atezolizumab+Cobimetinib (moved from 4 to 3A only in CRC)
            • MDM2 - Amplification - Liposarcoma - DS-3032b and RG7112 (new association)
            • PIK3CA - Oncogenic Mutations - Breast Cancer - Alpelisib+Fulvestrant, Buparlisib+Fulvestrant, Copanlisib, GDC0077, Serabelisib, Fulvestrant+Taselisib (new drugs added)
            4
            • EGFR alterations - Glioma - Erlotinib (removed)
            • MDM2 - Amplification - Liposarcoma - DS-3032b (moved to 3A)
            • PIK3CA - Oncogenic Mutations - Breast Cancer - Alpelisib+Fulvestrant (moved to 3A)
            • IDH1 - R132 alterations - Chondrosarcoma - AG-120 (moved from 3A to 4)

          December 29, 2016

          • Level 3 and 4 alterations supported by data from conference proceedings are now included in the Actionable Genes tab.

          November 22, 2016

          October 24, 2016

          • Inclusion of a selection of Level 4 associations in the Actionable Genes tab.
          • KRAS activating mutations are no longer considered Level 3A based on the completion of the SELECT-1 trial. Despite promising initial results, selumetinib did not have a significant effect on survival, and therefore activating KRAS mutations are now considered Level 4.

          September 16, 2016

          • Updated Actionable Genes.

          August 10, 2016

          • Improved visualization of OncoKB™ in cBioPortal:
          • Updated genes and alterations in the tables of Levels 1, 2 and 3 Actionable Genes.
          • Updated Levels of Evidence.

          July 6, 2016

          • Annotations for Level 1, 2 and 3 genes now include key updates from ASCO 2016.
          • The Levels of Evidence system now includes Level R1, comprising of alterations that are NCCN-compendium listed as a biomarker of resistance to an FDA-approved drug.

          July 6, 2016

          Improved clinical annotations:
          • Annotations for Level 1, 2 and 3 genes now include key updates from ASCO 2016.
          • The Levels of Evidence system now includes Level R1, comprising of alterations that are NCCN-compendium listed as a biomarker of resistance to an FDA-approved drug.

          Jun 6, 2016

          We are happy to announce the first release of OncoKB™, a knowledge base for precision medicine. Our goal is to comprehensively annotate the oncogenic effect of mutations observed in cancer, as well as their therapeutic implications. This release contains information about almost 3,000 alterations in 418 cancer genes. For each alteration, we categorize the biological and clinical effect, along with citations of the source of the information, and, when available, the therapeutic implications of a alteration. We have focussed on FDA-approved (Level 1) or guideline-listed (Level 2) biomarkers, as well as biomarkers that with clinical evidence for sensitivity and for which therapies are currently explored in clinical trials (Level 3). See the Levels of Evidence and Actionable Genes pages for more information.

          We have also integrated information from OncoKB™ into the cBioPortal for Cancer Genomics. When exploring alterations in cbioportal.org, you will see annotations from OncoKB™ when available. Example of a lung cancer case.